Investor relations
Menu
press releases
03/16/2023
PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy
03/14/2023
PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery
02/07/2023
PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement
PainReform Provides Business Update for the Third Quarter of 2022
11/08/2022
PainReform Provides Further Update on Manufacturing of PRF-110
10/04/2022
